Dahua Technology Unveils Full-color Cube to Explore New Possibilities of Innovation
19.4.2023 15:45:00 EEST | Business Wire | Press release
Dahua Technology, a world-leading video-centric AIoT solution and service provider, unveils the 2023 Full-color Cube concept —— a cube of color magic that combines Full-color, Smart Dual Light and other technologies into infinite possibilities of innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005078/en/
For years, Dahua has been investing in Full-color Technology that assures users 24/7 colorful monitoring as well as trust-worthy performance in terms of clarity, definition, flexibility, accuracy and intelligence. This year, meet Full-color Cube! It integrates Full-color and Smart Dual Light with other technologies, creating infinite possibilities for innovation and allowing you to do more than you could ever imagine. (Photo: Business Wire)
“Dahua’s Full-color technology is continuously being upgraded, with the addition of Smart Dual Light as one great example. This year, we combined these two core technologies with AI, Duo and PT cameras, as well as other technologies to offer the Full-color Cube that further addresses users’ monitoring needs for vivid and color images in low-light environments,” said Eaden Xie, Product Manager at Dahua Technology.
Featuring panoramic vision, more personalized and flexible settings, intelligence at will, and future growth, the Full-color Cube unlocks a wealth of cutting-edge security functions through strong technological combinations.
Full-color + Panoramic: seamless 180° wide-angle image
The Full-color Panoramic series achieves a wider range of vision coverage by utilizing the capabilities of both Full-color Duo and PT cameras.
- Full-color + Duo
Based on Dahua’s advanced pixel-level metadata fusion algorithm, Full-color Duo camera adopts Dual F1.0 Aperture Lens and Dual 1/1.8" CMOS Sensors to create better imaging effects in low-light conditions. Compared with traditional cameras, its seamless 180° image significantly saves equipment and installation costs. Also, the eyeball model supports 3-axis rotation, which makes installation and operation more convenient. Moreover, its EPTZ function features panoramic image with multiple target details.
- Full-color + PT
Equipped with larger pan & tilt angle, Full-color PT camera provides an expanded field of view with fewer blind spots, while capturing 24/7 color images for more information and details. A variety of mounting brackets makes it easy to install on a pole, ceiling, or wall.
TiOC: full-time protection before, during, and after an event
TiOC (Three-in-One Camera) is a star product of the Dahua Full-color family that integrates Smart Dual Light, Active Deterrence, and AI. Before the event, SMD 4.0 and Perimeter Protection technology accurately focuses on human and vehicle alarms. During the event, Smart Dual Light technology records events in color, while actively deterring intruders with red and blue lights and siren. After the event, Smart Search quickly retrieves target footages, reducing investigation time. TiOC also allows third-party platform access for live broadcast/playback, video and audio parameter configuration, etc.
For more details about Full-color Cubes, please visit here .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005078/en/
Contact information
Zoe Xu (xu_shuyi@dahuatech.com )
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom